TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03801096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Based Therapuetic Assessment (NbTa)
Description: The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry \& Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White \& Epston, 1990).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control Condition (HE)
Description: The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
Study: NCT01670461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACE
Description: FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care (SOC) Control
Description: Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy:  ... regarding advance directives ... to honor each non-minor patient's wishes ... to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions. Upon admission if they do not have an advance directive, they should be given the Advance Directive Information Booklet and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record.
Study: NCT02589639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For blinding purposes
Study: NCT03482479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone Hydrochloride
Description: Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: A placebo tablet which matches the drug will be taken daily for 6 weeks.
Study: NCT01742325

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: walking
Description: two 20-minute sessions of walking around the nurse's station daily, five days a cycle
Study: NCT03270137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation- IDLPFC
Description: Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation - Six regions
Description: Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
Study: NCT03765671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: 120mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: 120mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: 120mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: 120mg oral single dose
Study: NCT03409679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Murepavadin
Description: Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two anti-pseudomonal antibiotics
Description: Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
Study: NCT04797715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 tablets, taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken twice daily
Study: NCT00770315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Description: Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Description: Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Description: Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
Study: NCT05360433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone oral capsule
Description: Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone oral capsule
Description: Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
Study: NCT03409185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon 1 piece SA60AT lens
Description: Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO 1-piece AABOO lens
Description: Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
Study: NCT00359970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg
Description: A single 500 mg dose at the start of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 500 mg
Description: A single 500 mg dose at the start of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 1000 mg
Description: A single 1000 mg dose at the start of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A single loading dose at the start of treatment and then a dose after each loose stool

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A single loading dose at the start of treatment and then a dose after each loose stool
Study: NCT03114189

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: footbath

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: care of sleep

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: care of sleep
Study: NCT03354351

Intervention type: BEHAVIORAL
Intervention: Stepped-care model
Description: The intervention proposed in this study is a stepped-care model (comprising 3 steps) integrating cognitive-behavioural therapy or trauma-focused therapy and emotion-focused therapy that involves matching individuals to the most appropriate level of care, based on their specific needs . When patients do not show improvement they move to higher, more intensive levels of care.

Intervention type: BEHAVIORAL
Intervention: Stepped-care model
Description: The intervention proposed in this study is a stepped-care model (comprising 3 steps) integrating cognitive-behavioural therapy or trauma-focused therapy and emotion-focused therapy that involves matching individuals to the most appropriate level of care, based on their specific needs . When patients do not show improvement they move to higher, more intensive levels of care.

Intervention type: BEHAVIORAL
Intervention: Stepped-care model
Description: The intervention proposed in this study is a stepped-care model (comprising 3 steps) integrating cognitive-behavioural therapy or trauma-focused therapy and emotion-focused therapy that involves matching individuals to the most appropriate level of care, based on their specific needs . When patients do not show improvement they move to higher, more intensive levels of care.
Study: NCT02933385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Risks assessement
Description: Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Risks assessement
Description: Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Risks assessement
Description: Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
Study: NCT04498390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT02933385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Risks assessement
Description: Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
Study: NCT03249090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Self-Reporting of Symptoms
Description: At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Delivery
Description: Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
Study: NCT02717611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196 (acalabrutinib)
Description: ACP-196 100 mg to be administered orally (PO) twice a day BID.
Study: NCT04157348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab
Description: 3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo to Mepolizumab
Description: Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Benralizumab
Description: Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
Study: NCT06410066

Intervention type: OTHER
Intervention: no intervention
Study: NCT01660763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab PCA System/15 mcg
Description: 15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sufentanil NanoTab PCA System
Description: Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
Study: NCT00477191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
Study: NCT01289067

Intervention type: DRUG
Group type: OTHER
Intervention: Satraplatin
Description: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
Study: NCT01232257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 4 gifts of N-acetylcysteine 600 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 4 gifts of N-acetylcysteine 600 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 4 gifts of N-acetylcysteine 600 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 4 gifts of N-acetylcysteine 600 mg BID
Study: NCT04242186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury Liaison Service
Description: The Injury Liaison Service nurse will coordinate deprescribing of fall-related medications, osteoporosis management, staff support of behavior management using video case conferencing, and shared decision making with residents and/or families.
Study: NCT03735784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE consists of four group sessions. The AWARE curriculum involves sharing basic information on sexually transmitted diseases; providing condom use skills training; providing normative feedback on substance use and sexual risk behavior among young adults; discussing unrealistic beliefs about substance use and sexual risk; discussing potential benefits of both cutting down and stopping risky behaviors; and discussing risky situations and coping strategies.
Study: NCT02933385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based health discussions
Description: Create interactions between the employees.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based health discussions
Description: Create interactions between the employees.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based health discussions
Description: Create interactions between the employees.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based health discussions
Description: Create interactions between the employees.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOScuisine website
Description: Site that is personalized to the employee. It provides menus, grocery shopping list and other.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOScuisine website
Description: Site that is personalized to the employee. It provides menus, grocery shopping list and other.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOScuisine website
Description: Site that is personalized to the employee. It provides menus, grocery shopping list and other.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOScuisine website
Description: Site that is personalized to the employee. It provides menus, grocery shopping list and other.
Study: NCT00781625

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: UREX-cap-5
Description: Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: UREX-cap-5
Description: Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Y cap G-3
Description: Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
Study: NCT01694537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DLBS1033
Description: The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo is made with same size and shape with study drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is made with same size and shape with study drug.
Study: NCT01042457

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil
Description: Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
Study: NCT00035126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epothilone b
Study: NCT01024322

Intervention type: DRUG
Intervention: Ciprofloxicine or Vigamox or other.
Description: Ciprofloxicine or Vigamox or other to be used qid till epithelialized.

Intervention type: DRUG
Intervention: Nonsteroidal (Acular, Voltaren Xibrom, etc)
Description: Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
Study: NCT02570165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batefenterol
Description: Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batefenterol
Description: Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batefenterol
Description: Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batefenterol
Description: Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batefenterol
Description: Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/ Vilanterol
Description: Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
Study: NCT01024322

Intervention type: DRUG
Intervention: Steroid (FML, Pred Forte, Flarex, etc.)
Description: Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
Study: NCT02570165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
Study: NCT00572234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion SR
Description: 12 week course of bupropion SR 150 mg, BID